Unique Mechanism of Action (MOA)

T-cell engagers (TCEs) targeting tumor-associated antigens (TAAs) represent a validated therapeutic strategy; however, their success in solid tumors has been limited. Key challenges include on-target, off-tumor toxicity due to TAA expression in healthy tissues and cytokine release syndrome (CRS) from broad systemic T-cell activation.

In contrast to traditional antibodies or current conditionally activated antibodies (such as masking or pH-dependency), which modulate T-cell or TAA binding through stimulus-driven activation to overcome these challenges, our innovative CrossBody TCEs demonstrate exceptionally enhanced therapeutic index without requiring antibody modification or external stimuli. 

CrossBody platform constructs multi-specific antibodies with innovative fragment, featuring a unique mechanism of action (MOA), and making undruggable targets druggable

Unique MOA: The CrossBody platform constructs multispecific antibodies with an innovative fragment, featuring a unique mechanism of action (MOA) that enables both intra-molecular and inter-molecular interactions. This approach makes previously undruggable targets (such as low-expressed tumor-specific antigen (TSA) and TAA highly expressed in both tumor and normal cells) druggable.